Last reviewed · How we verify
Ramucirumab - SC
Ramucirumab - SC is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 1 development. Also known as: LY3009806.
Ramucirumab-SC is an antibody that inhibits vascular endothelial growth factor receptor 2. It is used to treat various stages of lung cancer, including advanced, recurrent, and stage III lung cancer, often in combination with other treatments such as docetaxel.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Eli Lilly and Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ramucirumab - SC |
|---|---|
| Also known as | LY3009806 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hyperhidrosis
- Excessive cerumen production
- Aphthous ulcer
- Diarrhoea
- Dyspepsia
- Nausea
- Toothache
- Feeling hot
- Injection site bruising
- Upper respiratory tract infection
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
Key clinical trials
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (PHASE1, PHASE2)
- Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (PHASE2, PHASE3)
- A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer (PHASE1)
- A Study of Ramucirumab (LY3009806) in Healthy Participants (PHASE1)
- Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramucirumab - SC CI brief — competitive landscape report
- Ramucirumab - SC updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Ramucirumab - SC
What is Ramucirumab - SC?
Who makes Ramucirumab - SC?
Is Ramucirumab - SC also known as anything else?
What development phase is Ramucirumab - SC in?
What are the side effects of Ramucirumab - SC?
Related
- Manufacturer: Eli Lilly and Company — full pipeline
- Also known as: LY3009806
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing